Review this journal

Cancer Immunology, Immunotherapy

SciRev ratings (provided by authors)

Duration of manuscript handling phases Click to compare
Duration first review round n/a compare →
Total handling time accepted manuscripts n/a compare →
Decision time immediate rejection n/a compare →
Characteristics of peer review process Click to compare
Average number of review reports n/a compare →
Average number of review rounds n/a compare →
Quality of review reports n/a compare →
Difficulty of reviewer comments n/a compare →
Overall rating manuscript handling n/a compare →

Latest review

No reviews have yet been submitted for this journal.

Journal info (provided by editor)

Issues per year
12
Articles published last year
151
Manuscripts received last year
396
% accepted last year
34
% immediately rejected last year
33
Open access status
optional
Manuscript handling fee?
no
Kind of complaint procedure
Editor
Two-year impact factor
4.85
Five-year impact factor
3.73
Disciplines: Immunology, Hematology, Oncology

Aims and Scope

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.